MedTrace Logo

Pharmacokinetic Study of Belviq in Adult Korean Volunteers

NCT01880502 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2013-10-14

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled, single-dose, dose escalation study (Phase I) to evaluate the tolerability and pharmacokinetics of Belviq in adult Korean volunteers.

Conditions

  • Healthy

Interventions

DRUG

Belviq 10mg

Belviq 10mg single dose administration

DRUG

Belviq 20mg

Belviq 20mg single dose administration

DRUG

Placebo

Placebo single dose administration

Sponsors & Collaborators

  • IlDong Pharmaceutical Co Ltd

    lead INDUSTRY

Principal Investigators

  • Kyoung Sang You, MD, PhD · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2013-07-31
Completion
2013-10-31

Countries

  • South Korea

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01880502 on ClinicalTrials.gov